摘要
目的探讨FLAG方案[氟达拉滨(Flud)联合阿糖胞苷(Ara-C)和粒细胞集落刺激因子(G-CSF)]治疗难治/复发急性髓性白血病(AML)的临床疗效及不良反应。方法采用FLAG方案[Flud 50 mg/d静脉滴注,连续5 d;Ara-C 1 000 mg/d,于Flud治疗后4 h开始持续静脉滴注,连续5 d;中性粒细胞计数≤1.0×109/L时给予G-CSF 5μg/(kg.d),皮下注射,直至WBC≥1.0×109/L]治疗AML患者15例,观察其疗效及不良反应。结果15例患者完全缓解8例,完全缓解率53.3%;部分缓解4例,总有效率80.0%;无效2例,死亡1例。主要不良反应为骨髓抑制、消化道症状、轻度肝损害等。结论FLAG方案治疗难治/复发性急性髓性白血病疗效好,患者对其耐受性好。
Objective To evaluate the efficacy and untoward reaction of FLAG protocol （ fludarabine,cytosine arabinoside and granulocyte colony stimulating factor） in treatment of refractory and relaps acute myelogenous leukemia To evaluate the efficacy and untoward reaction. Methods FLAG protocol [Flud 50mg/d iv gtt successive 5 days;Ara-C 1 000 mg/d iv gtt 5 days after using Flud 4 hours;G-CSF 5.0 μg/kg. d hypodermic begin with white blood count≤1. 0 × 10^9/L] was use to treat 15 case of refractory and relaps acute myelogenous leukemia. Results Of the 15 patients, 8 patients obtained complete remission （CR） and the CR rate was 53.3%,4 patients obtained partial remission ,the ove tall remission rate was 80.0 %. 2 case obtained non-remission 1 case dead . the main untoward reaction was myelosuppression, gastrointestinal tract symptoms or slight liver function harmfulness. Conclusion FLAG protocol show obvious efficacy for refractory and relaps acute myelogenous leukemia,and patiens tolerance it well.
出处
《江西医学院学报》
CAS
2009年第1期110-112,共3页
Acta Academiae Medicinae Jiangxi
